Capricor Therapeutics (CAPR) Income from Continuing Operations (2010 - 2026)
Capricor Therapeutics' (CAPR) quarterly Income from Continuing Operations came in at 33941345.0 in Q1 2026, down 39.15% year-on-year from 55780370.88 in Q1 2025, and down 5.85% quarter-over-quarter from 32066247.0 in Q4 2025.
Capricor Therapeutics (CAPR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 33941345.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 39.15% year-over-year to 33941345.0 in Q1 2026; TTM through Mar 2026 was 214929659.0, a 15.66% decrease from a year earlier, with the FY2025 full-year figure at 105043946.0, down 159.58% from the prior year.
- Income from Continuing Operations slipped to 33941345.0 in Q1 2026 per CAPR's latest filing, from 32066247.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1363730.0 in Q4 2023 and bottomed at 131058225.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 23147159.0 (2024), against an average of 31346057.94.
- Across the five-year window, Income from Continuing Operations jumped 81.52% in 2023 and tumbled 1133.65% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 7380806.0 in 2022, then soared by 81.52% to 1363730.0 in 2023, then slumped by 430.63% to 7236346.0 in 2024, then slumped by 343.13% to 32066247.0 in 2025, then dropped by 5.85% to 33941345.0 in 2026.
- Per Business Quant, the three latest CAPR Income from Continuing Operations figures stand at 33941345.0 (Q1 2026), 32066247.0 (Q4 2025), and 60205190.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - | -33.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.94 Mn |
| Dec 31, 2025 | -32.07 Mn |
| Sep 30, 2025 | -60.21 Mn |
| Jun 30, 2025 | -88.72 Mn |
| Mar 31, 2025 | -24.39 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Sep 30, 2024 | -131.06 Mn |
| Jun 30, 2024 | -23.15 Mn |
| Mar 31, 2024 | -41.22 Mn |
| Dec 31, 2023 | -1.36 Mn |
| Sep 30, 2023 | -10.62 Mn |
| Jun 30, 2023 | -19.48 Mn |
| Mar 31, 2023 | -8.23 Mn |
| Dec 31, 2022 | -7.38 Mn |
| Sep 30, 2022 | -24.24 Mn |
| Jun 30, 2022 | -11.68 Mn |
| Mar 31, 2022 | -7.90 Mn |
| Dec 31, 2021 | -6.23 Mn |
| Sep 30, 2021 | -10.04 Mn |
| Jun 30, 2021 | -5.07 Mn |